FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
Formac is a leading drug delivery company offering a unique mesoporous silica-based technology to enhance the oral bioavailability of poorly water-soluble drugs. The company is persuing a dual business model with partnering for NCE developments and developing reformulation products. Since its incorporation Formac has signed more than 40 feasibility agreements . To date, Formac is the only company that demonstrated the clinical relevancy of the silica based technology in a clinical setting.
FORMAC is a privately held company established in 2007 as a spin-off project from the University of Leuven (K.U.Leuven).
Thanks to its innovative silica based drug delivery platform, the company is supporting the development of New Chemical Entities (NCEs) suffering from poor aqueous solubility .
In addition, the company is actively involved in the reformulation of marketed products for the development of value added generics and/or Life Cycle Management Initiatives from pharmaceutical companies
Our mission is to increase pharmaceutical R&D productivity and product value by enhancing the performance of (pre)clinical drug candidates and marketed drugs.
FORMAC is a technology-based company applying a product-focused strategy with the objective to build over the next few years a balanced product-portfolio in one or two disease areas.
In order to fully exploit its unique technology platform, FORMAC applies a dual business approach using the proceeds generated by contract R&D activities to accelerate and expand its internal development programs, which eventually will be partnered with pharmaceutical and generic drug companies. This strategy will allow us to progressively increase value for our shareholders, employees, corporate partners and patients.